Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41)
US6114133A · kind A · utility
112Cited by
8References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 14, 1994 |
| Grant date | Sep 5, 2000 |
| Priority date | — |
| Expiry date | Nov 14, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/811
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-.beta. peptide (x-.gtoreq.41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.